Statement: the total number of adverse events was higher in cohort 1 than in cohort 2 in the primary clinical trial
Primary_evidence: Adverse Events 1:   Total: 13/61 (21.31%)   Anaemia 1/61 (1.64%)   Febrile neutropenia 1/61 (1.64%)   Cardiac failure congestive 0/61 (0.00%)   Pericardial effusion 0/61 (0.00%)   Constipation 1/61 (1.64%)   Intestinal perforation 1/61 (1.64%)   Stomatitis 0/61 (0.00%)   Non-cardiac chest pain 2/61 (3.28%)   Condition aggravated 1/61 (1.64%)   General physical health deterioration 1/61 (1.64%) Adverse Events 2:   Total: 12/60 (20.00%)   Anaemia 1/60 (1.67%)   Febrile neutropenia 0/60 (0.00%)   Cardiac failure congestive 1/60 (1.67%)   Pericardial effusion 1/60 (1.67%)   Constipation 0/60 (0.00%)   Intestinal perforation 0/60 (0.00%)   Stomatitis 1/60 (1.67%)   Non-cardiac chest pain 0/60 (0.00%)   Condition aggravated 0/60 (0.00%)   General physical health deterioration 1/60 (1.67%)